About

WHY EASL CREATED A FOUNDATION

For many years, the EASL Governing Board has heard from different partners and stakeholders about the need to extend the top level science and educational initiatives beyond Europe. EASL listened to the community and then analyzed the best way to respond in the most effective manner.

Following independent advice, the need to establish a dedicated vehicle to support this objective was clearly identified and executed in order for EASL to focus on its core activities derived from the latest scientific research and so that liver knowledge can be shared with everyone.

In 2016, the EASL International Liver Foundation was established by EASL and Professor Massimo Colombo was appointed as the board chairperson.

Learn more about our Foundation

 

The board

PROF. Massimo COLOMBO

Chairman

Massimo Colombo is Chairman of the EASL International Liver Foundation, Geneva, Switzerland. He is also Head of the Liver Center for Translational Research, IRCCS Humanitas, Milan, Italy. His research interests include the diagnosis and treatment of viral hepatitis, liver transplantation and liver cancer.
Read more.

Prof. Christian Bréchot

Board Member

Christian Bréchot has been the President of Institut Pasteur since October 1st, 2013. His research mainly focuses on viral hepatitis: hepatitis B (HBV) and C (HCV), particularly with regard to their role in liver cancer (Hepatocellular carcinoma: HCC) and to the molecular mechanisms that drive liver regeneration and cancer (in particular, cell cycle deregulation).  His research activities have led him to obtain 13 patents and to contribute to the creation of two biotech companies : Rarecells and ALFACT Innovation.
Read more.

Prof. Jordi BRUIX

Board Member

Jordi Bruix is Professor of Medicine at the University of Barcelona and Director of the Barcelona Clinic Liver Cancer (BCLC) Group within the Liver Unit at the Hospital Clinic of Barcelona, Spain. Prof. Bruix has been the principal investigator of studies and clinical trials that have changed practice in the field of hepatocellular carcinoma (HCC),  including  development  of  diagnostic criteria and prognostic models and establishment of chemoembolization, SORAFENIB and REGORAFENIB as EFFECTIVE therapy. He founded the International Liver Cancer Association (ILCA) and was its president from 2006 to 2009.
Read more.

Prof. Manal EL-SAYED

Board Member

Manal El-Sayed, MD, is Professor of Pediatrics at Ain Shams University, Cairo, Egypt, where she trained in medicine and subsequently completed her masters and doctorate in Pediatrics. Since 1990 she has worked in pediatric hematology and oncology teams developing a program for the management of liver disease in children and adolescents with hematological disorders, malignancies and recipients of bone marrow transplantation at Ain Shams University, National Cancer Institute and 57357 Children’s Cancer Hospital. She is a founding member of the Egyptian National Committee for Control of Viral Hepatitis (NCCVH) since 2006 charged with planning and implementing the nationwide program for prevention and management of viral hepatitis. Professor El-Sayed contributed to the establishment of 55 nationwide specialised liver centers connected through a database networking system for management of patients with viral hepatitis, where 350,000 HCV-infected patients received therapy with interferon.
Read more.

Prof. Jeffrey LAZARUS

Vice-Chairman

Prof Jeffrey V. Lazarus is an associate research professor at the Barcelona Institute of Global Health (ISGlobal), Hospital Clínic, University of Barcelona and an associate professor at the Faculty of Medicine, University of Barcelona, Spain. His decade-long career as a health systems, HIV and hepatitis expert at WHO’s Regional Office for Europe was followed by three years at the Global Fund to Fight AIDS, Tuberculosis and Malaria, where he led knowledge translation, and then 7 years at the WHO Collaborating Centre on HIV and Viral Hepatitis, in Copenhagen. He is the past director of Health Systems Global and former board chair of the foundation AFEW International.

Read more.

 

Prof. Francesco Negro

Prof. Francesco NEGRO

Board Member

Francesco Negro is Professor at the Departments of Medicine and of Pathology and Immunology of the University Hospitals of Geneva, Switzerland. He obtained his Medical Degree in 1982 at the University of Torino, Italy, where he also completed his postgraduate education in Gastroenterology. He was Visiting Scientist and then Assistant Professor at the Georgetown University School of Medicine, Rockville, MD, USA from1986 to 1989, and Guest Researcher at the Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA in 1989. After having spent some time back in Torino, he joined the University Hospitals of Geneva, Switzerland, in 1994. He was appointed Full Professor of the Faculty of Medicine, University of Geneva in 2014. His research interests focus on viral hepatitis, especially on the pathogenesis of metabolic alterations induced by the hepatitis C virus, i.e. steatosis and insulin resistance. More recently, he has participated into numerous collaborative works on epidemiology and public health issues related to viral hepatitis. He has participated in several clinical trials in acute and chronic HCV, authoring or co-authoring ~300 peer-reviewed manuscripts in the field of hepatology. After serving as Educational Councilor within the Governing Board of the European Association for the Study of the Liver (EASL), he is currently Treasurer of EASL for the period 2019-2024. He is also chairing the Swiss Hepatitis C Cohort Study, and is member of the updating panels of the clinical practice guidelines for HCV of the EASL and of the World Health Organisation.

PROF. ANDREA SIRONI

Board Member

Andrea Sironi is Professor of Banking and Finance at Bocconi University in Milan, where he has been Rector from 2012 to 2016. Since January 2016, he is Chairman of Borsa Italiana SpA and, since October 2016, a member of the Board of Directors of the London Stock Exchange Group. He is currently a member of the Board of Directors of Cassa Depositi e Prestiti SpA and of Cogentech Scarl.
Read more.

Prof. Dr. Phil N. NEWSOME

Board Member

Director of the Centre for Liver Research & Professor of Experimental Hepatology, University of Birmingham, and Consultant Hepatologist at the Liver Unit, Queen Elizabeth Hospital, Birmingham

He graduated from the Medical School at the University of Edinburgh in 1995 and moved to Birmingham in 2007.

He runs the metabolic services at the Liver Unit at the Queen Elizabeth Hospital Birmingham which includes a large multi-disciplinary clinic for patients with NAFLD. Professor Newsome has published over 75 research papers in scientific journals as well as many book chapters in the field of Non-Alcoholic Fatty Liver Disease (NAFLD). He was Chief Investigator on a randomised controlled trial of Glucagon-like peptide-1 (GLP-1) therapy in NAFLD published in the Lancet, and is also Chief Investigator on a study of Fibroscan in NAFLD. He is editor of a recently published textbook on Liver Transplantation, and chaired the national guidelines for liver transplantation in NAFLD. He sits on the NICE Guideline Development Group for NAFLD.

 

Prof. Mark THURSZ

Board Member

Mark Thursz is Professor of Hepatology at Imperial College where he is head of the Digestive Diseases Division and lead clinician for hepatology at St Mary’s Hospital, London. His clinical interests are in viral hepatitis, alcoholic and fatty liver disease.Prof. Thursz is

Prof. Thursz is chief investigator on two multi-centre trials: The warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C) trial and the steroids or pentoxifylline for alcoholic hepatitis (STOPAH) trial. He is chief investigator on the PROLIFICA programme in West Africa.
Read more.

Dr. Stefan WIKTOR

Board Member

Stefan Wiktor is a public-health physician with more than twenty-five years’ experience in epidemiologic research and the implementation of public-health programs. Dr Wiktor is Professor of Medicine and Public Health at the University of Washington in Seattle, U.S.

From 2012-2016, Dr. Wiktor was the Team Lead of the World Health Organization’s Global Hepatitis Programme in Geneva, Switzerland which provides guidance and technical assistance to countries to promote the implementation of comprehensive viral hepatitis prevention and control programs.
Read more.

Data Protection and Privacy Policy

EASL International Liver Foundation

We take the protection of your personal data seriously, meaning that we process your personal data with due care and in accordance with applicable data protection laws.

Consent

Please note that by clicking the box “I agree”, you explicitly agree to the processing of your personal data for the purposes and pursuant to the terms and conditions mentioned in our Data Protection and Privacy Policy available at here“.

Contact

For any question or request, please contact us at EASL International Live Foundation, Rue Daubin 7, 1203 Geneva, Switzerland, telephone 0041 (0)22 552 2497 gdpr@easl-ilf.org